1,2
the dose of As2O3 and IFN was set as the approved dose for the treatment of acute promyelocytic leukemia and chronic myelocytic leukemia respectively. This study was reviewed and approved by the Fukuoka University Ethics Committee and Institutional Review Board of Fukuoka University Hospital. The As2O3 solution was prepared as previously described.
7 All patients provided their written informed consent. Treatment response was determined by the criteria described by Yamada et al., 8 and toxicity was graded according to the National Cancer Institute Common Toxicity Criteria (NCI-CTC version 2.0).
Patients' characteristics and results of As2O3 therapy are summarized in Table 1 . Adverse events observed during the treatment were managed with standard approaches. Patients 1 and 2 were heavily treated with multiple conventional chemotherapeutic agents prior to As2O3 treatment and their performance status was poor. Furthermore, disease progression was extremely rapid as suggested by the evidence that, in these patients, doubling time of serum LDH levels which correlated with tumor burden was 1 to 3 days (data not shown). On the other hand, As2O3 and IFN therapy produced promising effects in patients 3 and 4, who achieved PR and improvement of thrombocytepenia caused by massive bone marrow infiltration of ATLL cells, respectively ( Figure 1 ). Most importantly, PR was maintained for as long as 8 months in patient 3 who had previously required uninterrupted conventional chemotherapy to avoid progression of ATLL.
Cytotoxicity of As2O3 and augmentation of its effects by combining with IFN in fresh ATLL cells obtained from patient 3 revealed in vitro by trypan blue exclusion dye. Peripheral blood mononuclear cells (PBMNC) were separated by Ficoll-Hipaque density sedimentation from heparinized peripheral blood obtained from patient 3 before starting the treatment. More than 90% of separated PBMNCs were ATLL cells as determined by the expression of CD4 and CD25 by flow cytometry. These cells were cultured with As2O3 (1.0 and 2.0 µM) and/or IFN (10 U/mL) for 120 hours. The concentrations of As2O3 were set according to pharmacokinetics in humans.
9,10 Treatment with As2O3 decreased the number of viable ATLL cells as compared with control in a dose and time dependently, and IFN which had been ineffective alone, significantly enhanced the effects of As2O3 (data not shown).
Patients included in our study had been much more heavily treated before As2O3 treatment than those in the French study. 4 It is difficult to determine the efficacy in patients 1 and 2 since disease progression was rapid and treatment was terminated early. Their clinical course suggests that As2O3 has a modest therapeutic potential, if any, on patients with heavily-treated and rapidly progressing ATLL. In contrast, the significant therapeutic response in patients 3 and 4 suggests that moderatelyaggressive ATLL could benefit from As2O3 therapy.
In conclusion, although this study involved only a 
